Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)

15 Jun 2023

Abstract excerpt

Homologous recombination deficiency (HRD) is a predictive marker for response to poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian carcinoma. HRD scores have entered routine diagnostics, but the influence of algorithms, parameters and confounders has not been analyzed comprehensively. A series of 100 poorly differentiated ovarian carcinoma samples was analyzed using whole exome sequencing (WES) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37327584
DOI: 10.1016/j.tranon.2023.101706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)PMID 37327584Read ↗

HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?Semantic proximity Read ↗

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.Semantic proximity Read ↗

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization ProjectSemantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Decoding HRD: A Genomic LOH-Based Assay Associated With Platinum Response and Survival in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Weakly-Supervised Tumor Purity Prediction From Frozen H&E Stained SlidesSemantic proximity Read ↗

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancerSemantic proximity Read ↗

Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancerSemantic proximity Read ↗

High-grade serous ovarian carcinoma and detection of inactivated BRCA genes from biopsy material of Slovak patients.Semantic proximity Read ↗

HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad’s myChoice®, SOPHiA GENETICS® SOPHiA Homologous Recombination Solution and AmoyDx® HRD Focus PanelSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.